Drug Trial Radar · NCT04906096
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jun 1, 2021
Primary completion
Dec 1, 2026
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Lakshmi Nayak, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kazia Therapeutics Limited
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Conditions
- Primary Central Nervous System Lymphoma
- Non-Hodgkin Lymphoma of Extranodal Site
Interventions
PAXALISIBDrug
Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Objective Response Rate (ORR)Time frame: Up to 24 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.